Autophagy delivers cytoplasmic constituents to autophagosomes and is involved in innate and adaptive immunity. Cytosolic phospholipase (cPLA 2 ) initiated pro-inflammatory lipid mediator pathways play a critical role in host defense and inflammation. The crosstalk between the two pathways remains unclear. Here, we report that cPLA 2 and its metabolite lipid mediators induced autophagy in the RAW246.7 macrophage cell line and in primary monocytes. IFN-γ triggered autophagy involves activation of cPLA 2 . Cysteinyl leukotrienes (CysLTs) D 4 and E 4 and Prostagladin D 2 (PGD 2 ) also induced these effects. The autophagy is independent of changes in mTOR or autophagic flux. cPLA 2 and lipid mediator-induced autophagy is ATG5 dependent. These data suggest that lipid mediators play a role in the regulation of autophagy, demonstrating a connection between the two seemingly separate innate immune responses, induction of autophagy and lipid mediator generation.
INTRODUCTION
Recently published studies have strongly indicated that autophagy is a host defense mechanism by which cells respond to microbial invasion and promote cell survival (1) (2) (3) (4) . Autophagy plays an important role in innate and adaptive immunity (5) (6) (7) (8) . The signals that activate autophagy and molecular tags guide the formation of double-membrane cytosolic vesicles. These vesicles, designated autophagosomes, sequester invading pathogens and their products, portions of the cytosol and damaged organelles. The autophagosomes ultimately fuse with other vesicles in the endolysosomal pathway to deliver microbial ligands for adaptive or innate immune activation, or with the lysosome for subsequent degradation in autolysosomes (9, 10) .
After an inflammatory stimulus, cells also may produce lipid mediators, such as leukotrienes or prostaglandins (11) . Those lipid messengers are derived from the poly-unstatuated fatty acid, arachidonic acid (AA). As the common precursor, AA is in turn converted to prostaglandins by cyclooxygenase (COX) pathway enzymes or to leukotrienes by the 5-lipoxygenase pathway (5-LO) (11, 12) . The enzyme which hydrolyzes AA release from membrane phospholipids is cytosolic phospholipase A 2 (cPLA 2 ), which is a rate-limiting enzyme that plays a key role in initiating and regulating the multistage biosynthetic process of eicosanoid production. cPLA 2 activation is involved in Toll-like Receptor (TLR)-induced innate immune signaling (13) . Therefore, a cPLA 2 -initiated pro-inflammatory lipid mediator pathway may play a pivotal role in the regulation of immune and inflammatory responses (14, 15) .
Since autophagy is a cellular defense mechanism and the cPLA 2 -initiated lipid mediator pathway is important for the production of lipid mediators and the promotion of the inflammatory response, we investigated the role of cPLA 2 and its lipid products in the induction of autophagy. Further, we studied whether they may participate in IFN-γ-induced autophagy in the macrophage. Here, we report that cPLA 2 and its lipid metabolites induce autophagy in the RAW264.7 macrophage cell line and in primary human peripheral blood monocytes. This pathway may also be important in IFN-γ-induced autophagy in macrophages. The induction of autophagy may be via an ATG5-dependent pathway. Therefore, cPLA 2 initiated lipid mediator generation may play a role in the autophagy response.
MATERIALS AND METHODS

Reagents and antibodies
Earle's Balanced Salt Solution (EBSS medium) was purchased from Thermo Scientific (Waltham, Mass). Murine and human interferon-γ were purchased from PeproTech Inc (Rock Hill, NJ). cPLA 2 and Leukotriene E 4 were purchased from Cayman Chemical Co (Ann Arbor, MI). Rabbit polyclonal antibodies against LC3 and actin were from Sigma-Aldrich (St. Louis, MO). Rabbit polyclonal antibodies against beclin-1 and ATG5 were purchased from Novus (Littleton, CO). A rabbit polyclonal antibody against cPLA 2 , rabbit anti-phosph S6K monoclonal antibody, and mouse anti-S6K monoclonal antibody were purchased from Cell Signaling Technology (Beverly, MA). Monoclonal antibody against GST was from Santa Cruz Biotechnology (Santa Cruz, CA). E64d and Pepstatin A were from Sigma-Aldrich (St. Louis, MO).
Cell culture
The murine macrophage cell line RAW264.7 was obtained from the American Type Culture Collection (ATCC; Manassas, VA) and maintained in Dulbecco's modified Eagle's medium (DMEM) (Biosource, Camarrillo, CA) supplemented with 10% fetal calf serum and 1% antibiotics PenStrep (GIBCO, Carlsbad, CA). Elutriated human peripheral blood monocytes were received from the Department of Transfusion Medicine, Clinical Center, under an institutional review board approved protocol. Cells were washed with PBS and maintained in human monocyte medium (Amaxa Inc, Gaithersburg, MD). For RAW264.7 cell starvation, cells were washed for once, cells were grown in EBSS for 2 hrs and harvested for S6K immunobloting.
Expression Plasmids and transient transfection
pEGFP-LC3 was a gift from Dr. Noboru Mizushima (The Tokyo Metropolitan Institute of Medical Science. Japan) (16) . For the cPLA 2 plasmid construct, the cPLA2 gene insert was prepared by PCR from pEGFP-cPLA2 (a gift from Dr. J. Evans and Dr. C. Leslie, National Jewish Medical Center, Denver, Co) (17) . The insert was then cloned into the mammalian expression GST plasmid. The correct sequence of the positive clones was confirmed by nucleotide sequencing based on the sequence of access number P47712. The plasmids were then transiently transfected into the RAW264.7 cells using FuGENE HD Transfection Reagent from Roche (Nutley, NJ) according to the manufacturer's protocol.
RNA Interference
The siRNAs of cPLA 2 , beclin-1, ATG5 and control small inhibitory RNAs (siRNA) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Cells were transfected with 30 pmol/ml siRNA by using Nucleofection electroporating transfection (Amaxa Inc, Gaithersburg, MD) following the manufacturer's directions. The interference of cPLA 2 , Beclin-1 or ATG5 protein expression was compared to control non-targeting siRNA and confirmed by immunoblotting.
Real-time PCR
Total RNA was extracted from cells using QIA Shredder columns and RNeasy mini kit and was treated with DNase (Qiagen, Valencia, CA). mRNA expression for IRG-47 (IFI-47) was measured using an ABI Prism 7900 sequence detection system (Applied Biosystems, Foster City, CA) and IFI-47 probe and primers sets (Applied Biosystems). Reverse transcription and PCR were performed using an RT kit and TaqMan Universal PCR master mix (Applied Biosystems), according to the manufacturer's directions. Relative gene expression was normalized to GAPDH transcripts, calculated as a fold-change compared with control.
[ 3 H]Arachidonic Acid Release
RAW264.7 cells were incubated overnight with 0.5 μCi of [5,6,8,9,11,12,14,15-3H] arachidonic acid (150-230 Ci/mmol/ml; GE Healthcare, Pascataway, NJ). Media was removed, the cells washed and incubated in control medium or in medium with interferon gamma for 6 hours. Media was harvested and an aliquot assayed in an LS 6500 scintilation counter (Beckman Instruments, Miami, Fla.).
Western Blot Analysis of RNAi-mediated knockdown of cPLA 2 , beclin-1 or ATG5 in RAW264.7 cells RAW264.7 cells and primary monocytes were grown in 6-well plates with stimuli or other treatment as indicated. The procedure of western blot analysis was carried out as previously described (13) . The primary antibodies were as indicated. For LC3 western blot, the cell lysis buffer was changed to PBS and 2% Triton X-100 (18) . Actin was used as a loading control.
Induction of autophagy
Cells were transfected with GST-cPLA 2 (1μg /well) for 24 h, or incubated with lipids (100nM) for 6 h, or alternatively, with IFN-γ (0.1μg/ml) for 6 h in nutrient medium.
Fluorescence laser scanning confocal microscopy RAW264.7 cells were grown on 35 mm glass bottom microwell dishes and transfected by pEGFP-LC3 and with the cPLA 2 expression plasmid or siRNA for 24 hrs, or different treatments as described. Cells were then fixed with −20° C methanol overnight in the dishes. The fixed cells were washed with PBS twice and kept in PBS. The green fluorescence labeled cells were observed and the numbers of LC3 positive autophagosomes in cells were quantified using a Leica DMIRB fluorescence inverted microscope with an 63x oil objective and TGS Sl confocal system. For the GFP-LC3 assay, a minimum of 100 GFP-positive cells per sample were counted and the number of GFP-LC3 aggregates were enumerated. Cells were scored as positive if they had more than three large GFP-LC3 puncta and the data were presented as a percentage of the total number of GFP-positive cells. The results are shown as the means ± S.D. from three independent experiments. Laser scanning images were cropped using Adobe Photoshop 5.0.
Electron microscopy
Cultures grown in Permanox tissue culture dishes (Nunc Nalgene) were fixed in 2.5% glutaraldehyde, 1% paraformaldehyde, 0.12M sodium cacodylate buffer, pH 7.3, postfixed in 1% OsO4 and en bloc stained with 1% uranyl acetate. The cultures were then dehydrated in graded ethanol and propylene oxide, infiltrated with Epon (Embed-812, Electron Microscopy Sciences) and the polymerized blocks were sectioned parallel to the culture substrate. Thin sections were stained with uranyl acetate and lead citrate, then viewed with a JEM-1200EX electron microscope (JEOL, USA) equipped with an AMT XR-60 digital camera (Advanced Microscopy Techniques). Images for quantification were taken with a 5000X electron microscope magnification setting from sections cut approximately midway between the adherent surface and the upper surface of the cell, such that cytoplasm occupied at least 2/3 of the image area. Structures of interest were counted in 44-47 digitally enlarged images corresponding to ~ half that number of cells each for experimentally treated and control cultures.
Statistical analysis
All statistical analyses were performed in Excel using a two-tailed T test. Where appropriate a Bonferroni adjustment was applied for multiple comparisons. A p value of <0.05 was considered significant.
RESULTS
Over-expression of cPLA 2 induces an autophagic response in macrophages
To detect autphagosome formation, green fluorescent protein fused to LC3 (GFP-LC3) was used as a marker of autophagy (5). Microtubule-associated protein light chain (LC3) is a homologue of ATG8 protein in yeast (16) . LC3 exists in two forms: the non-lipid form, cytosolic species LC3-I corresponding to the relative molecular mass (M r ) of 18 kD, and its membrane-associated form, LC3-II, conjugated C-terminally to phosphatidylethanolamine, with an apparent M r of 16 kD. The latter form, LC3-II is found both inside and outside the autophagosome. It can be used to document induction of autophagy (16) with increased levels of the autophagosome protein LC3-II on immunoblots or with the appearance of the cytoplasmic fluorescent puncta formed by inserted-GFP-LC3-II into the membrane of the autophagosome. To test whether cPLA 2 can induce autophagy, GFP-LC3 was co-transfected with the GST-vector or the GST-cPLA 2 -vector into RAW 264.7 macrophages for 24 h. Expression of the indicated proteins is shown on the immunoblot ( Figure 1A cPLA 2 is involved in IFN-gamma induced macrophage autophagy IFN-gamma induces autophagy in macrophages (1), a process that is important for eliminating intracellular bacterial infection and cell defense. However, the mechanism or pathway by which this occurs is not clear. Previous reports suggest that IFN-γ induces cPLA 2 activity in human epithelial cells and in HL-60 cells (19, 20) . Therefore, we next examined whether cPLA 2 participates in IFN-gamma-induced autophagy in macrophages. We first reduced the expression of endogenous cPLA 2 by transfecting two siRNAs directed against cPLA 2 into RAW264.7 macrophages and then treated the cells with or without IFN-γ. As demonstrated by immunoblotting, two cPLA 2 siRNAs reduced cPLA 2 expression in macrophages ( Figure 2A ) and the reduction of cPLA 2 expression impaired IFN-γ -induced autophagy based on the amount of endogenous LC3-II detected ( Figure 2B ). Further, RAW 264.7 macrophages were co-transfected with GFP-LC3 and cPLA 2 siRNA or the control scrambled siRNA. The formation of GFP-LC3 autophagosomes was analyzed with or without IFN-γ stimulation by confocal fluorescence microscopy. These images are shown in Figure 2C . Interferon-gamma induced autophagic vesicle formation. This response was reduced in cells treated with siRNA against cPLA 2 compared to cells treated with a control siRNA ( Figure 2C and 2D) . To further confirm that cPLA 2 is involved in IFN-γ-induced autophagy in macropahges, we utilized a pyrrolidine derivative cPLA 2 
HCl, to perform the above experiments (Figure 3) . Treatment of cells with this cPLA 2 inhibitor blocked IFN-gamma-induced AA release ( Figure 3B ). Consistent with the siRNA data, cPLA 2 inhibition partially blocked IFN-γ-induced autophagy as measured by localization of LC3 to autophagosomes or changes in LC3-II by immunoblot ( Figure 3D ). These results indicate that cPLA 2 at least in part regulates IFN-γ-induced autophagy in macrophages. In order to determine if the cPLA 2 inhibitor altered IFN-γ-induced transcription, the effect of the cPLA 2 inhibitor was studied on an IFN-gamma inducible gene. IRG-47 (IFI-47) is IFN-γ reducible gene that has distinct roles in immune defense against protozoan infections (21) . RAW264.7 cells were treated with or without cPLA 2 inhibitor (10uM) for 2 h before treatment of IFN-γ for 6 h. Cells were harvested and IRG-47 mRNA levels were determined by real-time PCR (RT-PCR) ( Figure 3E ). IFN-γ induction of IRG-47 was not altered by treatment with the cPLA 2 inhibitor, suggesting that cPLA 2 does not regulate IFN-γ gene induction.
cPLA 2 related eicosanoid mediators induce autophagy
Inflammatory lipid mediators (eicosanoids) are final metabolites of cPLA 2 activation. We examined the hypothesis that inflammatory lipid mediators are important in the induction of autophagy. A COX inhibitor, indomethacin or 5-Lo inhibitor, MK866, was used to treat RAW264.7 macrophages transfected with GFP-LC3 prior to IFN-γ stimulation. Either inhibition of COX or 5LO partially inhibited IFN-γ-induced GFP-LC3 autophagosome formation as compared with IFN-γ stimulation alone ( Figure 4A ), suggesting that the lipid mediators from either pathway may be involved in the induction of autophagy. We tested whether eicosanoids that are known to be produced by macrophages might induce these changes. cysLTD 4 and cysLTE 4 from the 5-Lo pathway and PGD 2 from the COX pathway induced an increase in the level of GFP-LC3 autophagosome formation ( Figure 4B and 4C ) and endogenous LC3-II formation ( Figure 4D ). LTB 4 , 5-HETE and PGE 2 had no significant effect. Arachidonic acid added to the media induced LC3-II ( Figure 4F ) suggesting that arachidonic acid may be metabolized to an active eicosanoid capable of inducing the autophagic response.
We next examined the autophagic response in primary cells, using monocytes separated from human peripheral blood. Human monocyte expression of endogenous LC3-II was assayed by immunobloting ( Figure 4E ). While no LC3-II was detected in untreated monocytes, IFN-gamma-induced an increase in LC3-II, which was partially inhibited by pretreatment with a cPLA 2 inhibitor. When monocytes were stimulated with the lipid mediators cysLTD 4 , cysLTE 4 or PGD 2 , LC3-II formation was again noted. Thus, a cPLA 2 -initiated lipid mediator pathway for the induction of autophagy is present in human monocytes.
Next, we examined the RAW264.7 macrophages by electron microscopy to look for early autophagosomes and autolysosomes ( Figure 5 ). Early autophagosomes were defined by the presence of a double membrane envelope surrounding a region of cytoplasm, whereas autolysosomes, also called late autophagosomes, were defined by a single membrane envelope with cytoplasmic content that appeared degraded or condensed. In addition to autophagosomes and autolysosomes, we observed tubular cytoplasmic structures with two membranes separated by a space of ~ 10 nm with an electron-dense core. Profiles of these tubular structures often occurred in clusters, suggesting that the structures could assume a curled configuration. We also noted many examples of these tubular structures surrounding areas of cytoplasm, which appeared to undergo degradation. Such compound structures were counted as autophagosomes or autolysosomes. We counted the total number of autophagosomes and autolysosomes in 44-47 fields from ~ 20 cells each from control and cysLTD 4 -treated cultures. cysLTD 4 -treated cells had 1.8-fold more autophagosomes or autolysosomes per field than control cells. Moreover, 49% of the fields had 3 or more autophagic structures in CysLTD 4 -treated cells compared to 18% in controls. These results are consistent with the increased abundance of LC3-positive autophagosomes ( Figure 4B ) in CysLTD 4 -treated cells. We also counted the number of widely separated individual profiles and clusters of profiles of the tubular dense-core structures. We found 1.7-fold more of these structures in CysLTD 4 -treated cells than in controls.
Autophagy induced by cPLA 2 over-expression is ATG5-dependent
Beclin-1 and ATG5 are central regulators in autophagy (22, 23) . Beclin-1 is a component of the class III phosphatidylinositol 3-kinase (PI3KC3) complex, which involves vesicle nucleation in the early stage of autophagy. ATG5 participates in the vesicle elongation of autophagy (24) . We reduced the expression of beclin-1 and ATG5 in RAW264.7 macrophages by transfection with beclin-1 or ATG5 siRNA ( Figure 6A and 6B) . GFP-LC3 autophagosomes were observed with cPLA 2 , siRNAs targeting beclin-1 or ATG5 and GFP-LC3 co-transfection for 24 hrs. Knockdown of ATG5 appeared to inhibit cPLA 2 -induced changes in GFP-LC3 autophagosome formation ( Figure 6C ). Similarly cells were stimulated with cysLTD 4 after transfection with siRNAs against beclin-1 or ATG5 and GFP-LC3 cotransfection for 24 h. GFP-LC3 autophagosomes were again increased by cysLTD 4 treatment. This increase was reduced in cells treated with siRNA against ATG5 relative to the cells transfected with control non-specific siRNA (NC siRNA) or siRNA against beclin-1 ( Figure 6D ). Endogenous LC3-II protein was deceased in cells transfected with siRNA against ATG5 ( Figure 6E ). These data suggest that the cPLA 2 initiated pathway induced autophagy is ATG5 dependent.
We further studied the effect of LTD 4 on cellular processes which might effect autophagosome accumulation. In order to determine if LC3-II accumulation is an effect of increased autophagy or a result of a block in autophagic flux, RAW264.7 cells were treated with or without lysozome inhibitors E64d and Pepstatin A and changes in LC3-II analyzed by western blot ( Figure 7A ). Pepstatin A and E64d treatment appeared to increase LC3-II accumulation in cells not treated with LTD 4 but to a greater degree in cells treated with LTD 4 . Therefore, LC3-II accumulation in LTD 4 treated cells does not appear to be a result of inhibition of autophagic flux. In order to determine if the effect of LTD 4 on LC3-II accumulation might be the result of mTOR inhibition, phospho-S6K was determined by western blot. Treatment of RAW264.7 cells with LTD 4 was not associated with a decrease in the phosphorylation of the mTOR substrate, S6K. As a control, amino acid starvation of these cells was associated with inhibition of S6K phosphorylation ( Figure 7B ).
DISCUSSION
In this report, we explored whether a cPLA 2 initiated lipid mediator pathway participates in the induction of autophagy. We observed that a cPLA 2 -initiated lipid mediator pathway induces autophagy in both a murine macrophage cell line (RAW264.7) and in human primary monocytes. The induction may be ATG5-dependent and independent of autophagic flux or mTOR inhibition. The autophagy induction may be due to the action of lipid mediators generated downstream of cPLA 2 . In addition, lipid mediators appear to be involved in IFN-γ-induced autophagy, suggesting that cPLA 2 initiated lipid mediators may be downstream effectors of IFN-γ signaling for autophagy.
Autophagy has been implicated previously in both health-promoting and disease-associated states. It has been thought to be a cellular homeostatic mechanism. Autophagy has been described in a variety of processes including neoplasia, neurodegeneration, myopathies, development, aging, innate and adaptive immune responses (5, 8) . Lipid mediators also may play a role in regulating immune and inflammatory responses (25) . Our results have linked two events, autophagy and cPLA 2 -initiated lipid mediator generation, which may bridge two aspects of the innate immune response. It is suggested that lipid mediator induced inflammation may in part regulate autophagy induction.
Lipid mediators are likely key participants in the pathogenesis of inflammatory diseases (26) . Our inhibitor and lipid mediator stimulation data suggest that autophagy was induced by the lipid products from two multi-enzyme pathways downstream of cPLA 2 . LTB 4 and LTC 4 are products of the 5-Lo pathway of AA metabolism. LTC 4 is converted extracellularly to LTD 4 and LTE 4 . Consequently, LTC 4 , LTD 4 , and LTE 4 are together referred to as cysteinyl leukotrienes (CysLTs). On the basis of multiple assays, including western blots, immunofluorescence microscopy and electron microscopy, we have shown that a subset of lipid mediators can induce autophagy in murine macrophages. Autophagy induction was observed with CysLT D 4 /E 4 and Prostgladin D 2 (PGD 2 ) treatment; but not with LTB 4, 5-HETE or PGE 2 . These data suggest that specific receptor expression signaling is associated with the lipid mediator induction of autophagy in murine macrophages (27) .
CysLTs and PGD 2 exert their actions through activation of their receptors, such as CysLT subtype 1 receptor (CysLT 1 ) (28), CysLT 2 (29) and PGD 2 receptor (DP) (30) . These are seven transmembrane domain G protein-coupled receptors that bind ligands to mediate intercellular signaling of inflammatory and other cells. The mechanism by which the signaling of lipid mediators may induce autophagy is not clear. Monocytes and macrophages can produce pro-inflammatory eicosanoids and express the CysLT receptors on the cell surface (31) . cysLTs modify macrophage functions. For instance, LTD 4 primes alveolar macrophages to release macrophage inflammatory protein 1α, TNF-α, and nitric oxide on exposure to inflammatory mediators (31) . It may induce autophagy as well.
The autophagy induced by lipid mediators may be an aspect of cellular responses against microbial invasion. Previous research suggested that several lipids could modulate the macrophage innate immune response against mycobacteria and enhance their killing (32) . Both NF-κB-dependent and -independent mechanisms are involved in macrophage killing of mycobacteria and both mechanisms can be enhanced by selected lipids.
The cPLA 2 -initiated lipid mediator pathway that induces autophagy appears to be ATG5-dependent. It may involve autophagic vesicle elongation. Several other proteins have been shown to bind ATG5. For example, in hepatitis C virus (HCV) infection, ATG5 is an interacting protein for the HCV NS5B protein (33) . ATG5 may also contribute to autophagic cell death by interacting with Fas-associated protein with death domain (FADD) (34) . The mechanism by which ATG5 may participate in the cPLA 2 -initiated lipid mediator pathway induced autophagy remains to be determined. In conclusion, cPLA 2 acting via generation of lipid mediators, appears to be capable of inducing or amplifying an autophagic response in monocytes and macrophages. Electron micrographs of the cytoplasm of RAW246.7 cells. Both control cells (a) and cells treated with CysLTD 4 for 6 h (b and c) contained early autophagosomes with an irregular double membrane envelope (large arrows, not shown in control), late autophagosomes or autolysosomes with a single membrane envelope (large arrowheads) and irregular tubular structures with a double membrane and a dense core (small arrows). The latter structures often appear to wrap around areas of cytoplasm, forming an autophagosome (small arrowheads). Both the autophagosomes/autolysosomes and the tubular dense core structures were more abundant in the cysLTD 4 -treated cells than in controls (see Results). Reference bar = 1μm. LTD 4 -induced autophagy is not regulated at the level of autophagic flux or by mTOR. (A) RAW264.7 cells were treated with or without lysozome inhibitors E64d (5 ug/ml) and Pepstatin A (5 ug/ml) and with or without LTD 4 (100 nM) for 6 hr. Cells were harvested for immunoblotting of LC3. Actin is used as a loading control. The induction of LC3-II appeared to be enhanced by pretreatment with E64d and Pepstatin A. The blot is representative of two blots with similar results. The average and range of the ratio of the density of blots of LC3-II/LC3-I is presented below the blot. (B) mTOR activity was assayed by western blot of phospho-S6K. RAW264.7 cells were treated with or without LTD 4 for the indicated times or with amino acid starvation with EBSS for 2 hr as a control and then harvested for immunoblotting for LC3.
